Mechanistic elucidation of inflammasome assembly and regulation. Supplement: Testing drugs that curtail inflammasome activation to suppress SARS-CoV-2 pathogenesis
Mechanistic elucidation of inflammasome assembly and regulation. Supplement: Testing drugs that curtail inflammasome activation to suppress SARS-CoV-2 pathogenesis
批准号:
10159600
负责人:
Judy Lieberman
金额:
$26.5万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-07-01 至 2021-06-30
关键词:
3-DimensionalApoptosisAutoimmune DiseasesBiologicalCASP1 geneCOVID-19COVID-19 pandemicCaspaseCaspase InhibitorCell DeathCell LineCellsCharacteristicsClinicalClinical TrialsComplexCoronavirusDataDeteriorationDiseaseDisease ProgressionDisulfiramEpithelial CellsExhibitsFDA approvedHDAC6 geneHealthHost DefenseImmune responseImmunologyInfectionInfiltrationInflammasomeInflammatoryInterleukin-18InterruptionLinkLungLung InflammationLymphocyteLymphopeniaMediatingMicrotubulesMiddle East Respiratory Syndrome CoronavirusMolecularNatural ImmunityNaturePathogenesisPathway interactionsPatientsPeptide HydrolasesPeripheral Blood Mononuclear CellPharmaceutical PreparationsPhysiologicalPneumoniaProteinsRegulationReportingResearch PersonnelRoleSARS coronavirusScienceSepsisSevere Acute Respiratory SyndromeSignal TransductionStructureTestingTherapeuticVDAC1 geneViralVirus ReplicationWorkautoinflammatorybasechemokinecytokinecytokine release syndromedrug testinghuman diseasein vitro Modelinhibitor/antagonistinterleukin-1beta-converting enzyme inhibitormarenostrinmicrobialmonocyteparticlepathogenrecruitresponsesensortool
中文摘要
摘要
炎性小体是一种超分子信号复合物,可激活半胱天冬酶的一个亚类
称为炎性半胱天冬酶如半胱天冬酶-1。在微生物的刺激下,
损伤相关的信号,炎性小体组装引发宿主防御的第一道防线,
细胞因子IL-1b和IL-18的蛋白水解成熟,以及通过诱导热凋亡细胞死亡。
炎性小体的组装需要激活上游传感器、下游传感器和下游传感器。
效应物,且在大多数情况下是衔接分子,如凋亡相关斑点样蛋白
含有胱天蛋白酶募集结构域(ASC)。根据是否需要ASC,
炎性小体可分为ASC依赖型和ASC非依赖型
炎性小体尽管炎性小体在先天免疫中具有生物学重要性,但没有
结构和机械信息是可用的。
这项提议试图将SARS-CoV-2感染与炎性小体联系起来,并测试是否
炎性体抑制剂减轻SARS-CoV-2的发病机制。炎性小体激活,
特别是通过NLRP 3炎性体和孔形成蛋白GSDMD,
严重的,往往是致命的细胞因子风暴,肺部炎症和败血症,
严重急性呼吸道综合征2型临床恶化它甚至可能导致淋巴细胞减少症,这是一个重要的
严重COVID-19病例的特征。这些数据来自SARS-CoV-2和相关的
冠状病毒,SARS-CoV和MERS-CoV,使我们提出了以下假设:
由SARS-CoV-2引起的严重急性呼吸综合征(SARS)肺炎是由
大量炎性细胞浸润和促炎细胞因子/趋化因子升高
依赖于GSDMD和/或NLRP 3激活的应答。
英文摘要
Abstract
Inflammasomes are supramolecular signaling complexes that activate a subset of caspases
known as inflammatory caspases such as caspase-1. Upon stimulation by microbial and
damage-associated signals, inflammasomes assemble to elicit the first line of host defense by
proteolytic maturation of cytokines IL-1b and IL-18, and by induction of pyroptotic cell death.
Assembly of an inflammasome requires activation of an upstream sensor, a downstream
effector, and in most cases an adaptor molecule such as apoptosis-associate speck-like protein
containing a caspase recruitment domain (ASC). Depending on whether ASC is required,
inflammasomes can be categorized into ASC-dependent and ASC-independent
inflammasomes. Despite the biological importance of inflammasomes in innate immunity, no
structural and mechanistic information is available.
This proposal seeks to link SARS-CoV-2 infection to inflammasomes and to test whether
inflammasome inhibitors alleviate SARS-CoV-2 pathogenesis. Inflammasome activation, in
particular through the NLRP3 inflammasome and the pore forming protein GSDMD, underlies
the serious, and often fatal cytokine storm, lung inflammation and sepsis that are associated
with SARS-CoV-2 clinical deterioration. It may even contribute to lymphopenia, an important
characteristic of severe COVID-19 cases. These data from SARS-CoV-2 and from related
coronaviruses, SARS-CoV and MERS-CoV, led us to propose the following hypothesis: the
severe acute respiratory syndrome (SARS) pneumonia induced by SARS-CoV-2 is caused by
massive inflammatory cell infiltration and elevated proinflammatory cytokine/chemokine
responses that depend on GSDMD and/or NLRP3 activation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Tumor-targeted disruption of mismatch repair in microsatellite stable colorectal cancer
-
批准号:10578049
-
项目类别:
-
资助金额:$24.82万
-
财政年份:2022
-
负责人:Judy Lieberman
-
依托单位:
Gasdermin E and pyroptosis in cancer
-
批准号:10375415
-
项目类别:
-
资助金额:$49.4万
-
财政年份:2020
-
负责人:Judy Lieberman
-
依托单位:
Gasdermin E and pyroptosis in cancer
-
批准号:10583571
-
项目类别:
-
资助金额:$49.4万
-
财政年份:2020
-
负责人:Judy Lieberman
-
依托单位:
Endogenous ligand of the NK activating receptor NKp46
-
批准号:10116279
-
项目类别:
-
资助金额:$22.13万
-
财政年份:2020
-
负责人:Judy Lieberman
-
依托单位:
Decidual NK response to infection
-
批准号:10160812
-
项目类别:
-
资助金额:$83.58万
-
财政年份:2019
-
负责人:Judy Lieberman
-
依托单位:
Decidual NK response to infection
-
批准号:10462767
-
项目类别:
-
资助金额:$83.58万
-
财政年份:2019
-
负责人:Judy Lieberman
-
依托单位:
Decidual NK response to infection
-
批准号:10623205
-
项目类别:
-
资助金额:$83.58万
-
财政年份:2019
-
负责人:Judy Lieberman
-
依托单位:
Granulysin, Granzymes and Perforin in Bacterial Immune Defense
-
批准号:9222706
-
项目类别:
-
资助金额:$44.25万
-
财政年份:2016
-
负责人:Judy Lieberman
-
依托单位:
Control of placental infection by decidual NK cell secreted granulysin
-
批准号:9236206
-
项目类别:
-
资助金额:$21.63万
-
财政年份:2016
-
负责人:Judy Lieberman
-
依托单位:
Control of placental infection by decidual NK cell secreted granulysin
-
批准号:9092639
-
项目类别:
-
资助金额:$27.68万
-
财政年份:2016
-
负责人:Judy Lieberman
-
依托单位:
Aptamer-siRNA gene knockdown to treat epithelial triple negative breast cancer
-
批准号:9766827
-
项目类别:
-
资助金额:$39.27万
-
财政年份:2015
-
负责人:Judy Lieberman
-
依托单位:
Aptamer-siRNA gene knockdown to treat epithelial triple negative breast cancer
-
批准号:8884851
-
项目类别:
-
资助金额:$40.38万
-
财政年份:2015
-
负责人:Judy Lieberman
-
依托单位:
IVIS Spectrum for In Vivo Imaging
-
批准号:8447806
-
项目类别:
-
资助金额:$41.8万
-
财政年份:2013
-
负责人:Judy Lieberman
-
依托单位:
Interferon Effects on HIV Transmission in Human Models
-
批准号:8852531
-
项目类别:
-
资助金额:$82.2万
-
财政年份:2012
-
负责人:Judy Lieberman
-
依托单位:
Interferon Effects on HIV Transmission in Human Models
-
批准号:8410956
-
项目类别:
-
资助金额:$11.92万
-
财政年份:2012
-
负责人:Judy Lieberman
-
依托单位:
CD4 aptamer-siRNA chimeras to prevent HIV transmission
-
批准号:8473156
-
项目类别:
-
资助金额:$76.64万
-
财政年份:2012
-
负责人:Judy Lieberman
-
依托单位:
Interferon Effects on HIV Transmission in Human Models
-
批准号:8463121
-
项目类别:
-
资助金额:$82.2万
-
财政年份:2012
-
负责人:Judy Lieberman
-
依托单位:
Interferon Effects on HIV Transmission in Human Models
-
批准号:8659072
-
项目类别:
-
资助金额:$23.97万
-
财政年份:2012
-
负责人:Judy Lieberman
-
依托单位:
Interferon Effects on HIV Transmission in Human Models
-
批准号:9064745
-
项目类别:
-
资助金额:$82.2万
-
财政年份:2012
-
负责人:Judy Lieberman
-
依托单位:
Interferon Effects on HIV Transmission in Human Models
-
批准号:8667986
-
项目类别:
-
资助金额:$82.2万
-
财政年份:2012
-
负责人:Judy Lieberman
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: